Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Venetoclax and Azacitidine in Accelerated or Blast Phase BCR-ABL Negative Myeloproliferative Neoplasm
NCT05074355Phase 2Recruiting
- Sponsor
- University Health Network
- Start
- Nov 2023
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of venetoclax, azacitidine in Myeloproliferative Neoplasm (MPN), sponsored by University Health Network. Started Nov 2023; status: recruiting.
02
Drugs
venetoclaxazacitidine
03
Conditions
Myeloproliferative Neoplasm (MPN)
Beyond the preview
Go deeper on NCT05074355.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05074355.